EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Assessing the reduction of viral infectivity in HPV16/18-positive women after one, two, and three doses of Gardasil-9 (RIFT): Study protocol

Victoria López-Codony iD, Álvaro de Andrés-Pablo, Angelica Ferrando-Díez, Maria Eulàlia Fernández-Montolí, Marta López-Querol iD, Sara Tous iD, Carlos Ortega-Expósito, Juan Carlos Torrejón-Becerra, Yolanda Pérez, Anna Ferrer-Artola iD, Josep Maria Sole-Sedeno iD, Clara Grau und 8 weitere

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0304080 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift PLOS ONE, 2024. Verfasst von Victoria López-Codony und 19 weiteren Autor:innen. Beteiligte Einrichtung: Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), Cancer Epidemiology Research Programme, L'Hospitalet de Llobregat, …. Hauptthemen laut MEDLINE: Human papillomavirus 16, Human papillomavirus 18, Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18, Papillomavirus Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, MSD, Departament d'Empresa i Coneixement, Generalitat de Catalunya.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human Papillomavirus (HPV) prophylactic vaccination has proven effective in preventing new infections, but it does not treat existing HPV infections or associated diseases. Hence, there is still an important reservoir of HPV in adults, as vaccination programs are mainly focused on young women. The primary objective of this non-randomized, open-label trial is to evaluate if a 3-dose regimen of Gardasil-9 in HPV16/18-positive women could reduce the infective capacity of their body fluids. We aim to assess if vaccine-induced antibodies could neutralize virions present in the mucosa, thus preventing the release of infective particles and HPV transmission to sexual partners. As our main endpoint, the E1^E4-HaCaT model will be used to assess the infectivity rate of cervical, anal and oral samples, obtained from women before and after vaccination. HPV DNA positivity, virion production, seroconversion, and the presence of antibodies in the exudates, will be evaluated to attribute infectivity reduction to vaccination. Our study will recruit two different cohorts (RIFT-HPV1 and RIFT-HPV2) of non-vaccinated adult women. RIFT-HPV1 will include subjects with an HPV16/18 positive cervical test and no apparent cervical lesions or cervical lesions eligible for conservative treatment. RIFT-HPV2 will include subjects with an HPV16/18 positive anal test and no apparent anal lesions or anal lesions eligible for conservative treatment, as well as women with an HPV16/18 positive cervical test and HPV-associated vulvar lesions. Subjects complying with inclusion criteria for both cohorts will be recruited to the main cohort, RIFT-HPV1. Three doses of Gardasil-9 will be administered intramuscularly at visit 1 (0 months), visit 2 (2 months) and visit 3 (6 months). Even though prophylactic HPV vaccines would not eliminate a pre-existing infection, our results will determine if HPV vaccination could be considered as a new complementary strategy to prevent HPV-associated diseases by reducing viral spread. Trial registration : https://clinicaltrials.gov/ct2/show/NCT05334706 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Human papillomavirus 16Human papillomavirus 18Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18Papillomavirus InfectionsAdolescentAdultFemaleHumansYoung AdultAntibodies, ViralCervix UteriDNA, ViralPapillomavirus VaccinesVaccinationClinical Trials as TopicEvaluation Studies as Topic

Substanzen

Antibodies, ViralDNA, ViralHuman Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18Papillomavirus Vaccines

Autor:innen und Institutionen

  • Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), Cancer Epidemiology Research Programme, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Programa de Doctorat en Biomedicina, Universitat de Barcelona (UB), Barcelona, Spain.
  • Medical Oncology Department, Catalan Institute of Oncology, Germans Trias i Pujol University Hospital (HGTiP), Badalona, Barcelona, Spain.
  • Department of Gynaecology, Bellvitge University Hospital (HUB), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Biomedical Research Networking Center for Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Bellvitge Biomedical Research Institute (IDIBELL), Pharmacy Unit, Bellvitge University Hospital (HUB), L'Hospitalet de Llobregat, Barcelona, Spain.

ORCID-Profile: Victoria López-Codony, Marta López-Querol, Sara Tous, Anna Ferrer-Artola, Josep Maria Sole-Sedeno, Paula Peremiquel-Trillas, Miquel Angel Pavón

Förderung

  • Instituto de Salud Carlos III
  • MSD
  • Departament d'Empresa i Coneixement, Generalitat de Catalunya

Zitieren

APA

López-Codony, V., de Andrés-Pablo, Á., Ferrando-Díez, A., Fernández-Montolí, M. E., López-Querol, M., Tous, S., Ortega-Expósito, C., Torrejón-Becerra, J. C., Pérez, Y., Ferrer-Artola, A., Sole-Sedeno, J. M., Grau, C., Rupérez, B., Saumoy, M., Sánchez, M., Peremiquel-Trillas, P., Bruni, L., Alemany, L., Bosch, F. X., & Pavón, M. A. (2024). Assessing the reduction of viral infectivity in HPV16/18-positive women after one, two, and three doses of Gardasil-9 (RIFT): Study protocol. PLOS ONE. https://doi.org/10.1371/journal.pone.0304080

Vancouver

López-Codony V, de Andrés-Pablo Á, Ferrando-Díez A, Fernández-Montolí ME, López-Querol M, Tous S, et al. Assessing the reduction of viral infectivity in HPV16/18-positive women after one, two, and three doses of Gardasil-9 (RIFT): Study protocol. PLOS ONE. 2024. doi:10.1371/journal.pone.0304080

BibTeX
@article{LpezCodony2024,
  author = {López-Codony, Victoria and de Andrés-Pablo, Álvaro and Ferrando-Díez, Angelica and Fernández-Montolí, Maria Eulàlia and López-Querol, Marta and Tous, Sara and Ortega-Expósito, Carlos and Torrejón-Becerra, Juan Carlos and Pérez, Yolanda and Ferrer-Artola, Anna and Sole-Sedeno, Josep Maria and Grau, Clara and Rupérez, Blas and Saumoy, Maria and Sánchez, Mónica and Peremiquel-Trillas, Paula and Bruni, Laia and Alemany, Laia and Bosch, Francesc Xavier and Pavón, Miquel Angel},
  title = {Assessing the reduction of viral infectivity in HPV16/18-positive women after one, two, and three doses of Gardasil-9 (RIFT): Study protocol},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0304080}
}
Kostenlos starten →